Structure Therapeutics Inc is a clinical stage global biopharmaceutical company focused on discovering and developing oral small molecule therapeutics for chronic diseases with unmet medical need. The company uses a structure based drug discovery platform that combines expertise in GPCR structural biology with computational chemistry methods to design molecules that modulate protein coupled receptors. Its lead candidate aleniglipron also known as GSBR 1290 is an oral small molecule selective GLP1R agonist currently evaluated in multiple Phase 2 studies for obesity overweight and related conditions. In addition the company advances two oral small molecule amylin receptor agonists ACCG 2671 and ACCG 3535 which are in Phase 1 and preclinical stages respectively. The pipeline also includes early stage programs targeting GIP receptors and glucagon receptors for potential combination therapy. Further programs investigate APJ receptor agonism for pulmonary arterial hypertension and LPA1 receptor antagonism for idiopathic pulmonary fibrosis. The company highlights a current manufacturing capacity of six thousand tons per year of aleniglipron which it states is sufficient to supply treatment to more than one hundred twenty million patients annually. All research development and intellectual property are held through wholly owned subsidiaries such as Gasherbrum Bio Aconcagua Bio Gimigela Bio Annapurna Bio and Lhotse Bio.

Structure Therapeutics Inc generates revenue primarily through upfront payments milestone payments and royalties from strategic collaborations and licensing agreements. The company has a collaboration agreement with Schrödinger that provides computational chemistry support and requires monthly active program payments in the low six digits. Under this agreement Schrödinger is entitled to milestone payments up to an aggregate of eighty nine million dollars for the first Aconcagua collaboration product to achieve a particular milestone event and tiered royalties in the low single digit range on worldwide net sales of collaboration products. In December 2025 the company signed a license agreement with Genentech and Roche granting a non exclusive royalty bearing license on certain patents covering a class of oral GLP1R agonists distinct from aleneglipron. Under this agreement Genentech paid an upfront non refundable payment of one hundred million dollars within thirty days of execution and agreed to pay royalties at a low single digit rate on net sales of the licensed products. Additional revenue may arise from future milestone payments under the Schrödinger collaboration as development programs advance and from potential royalties if licensed product candidates reach commercialization. The company does not yet market any product so its current revenue consists of these collaboration and licensing proceeds.

Structure Therapeutics Inc positions itself as an innovator in the oral small molecule arena for GPCR targets where peptide and biologic therapies currently dominate the market. Competitors developing oral small molecule GLP1R agonists include Pfizer Eli Lilly Qilu Regor Therapeutics AstraZeneca Eccogene Terns Pharmaceuticals Jiangsu Hengrui Medicine Huadong Sciwind Biosciences Ascletis Gilead Kallyope MindRank vTv Therapeutics Carmot Therapeutics Kailera Therapeutics and Merck. Approved peptide GLP1R agonists are sold by Novo Nordisk Eli Lilly AstraZeneca Sanofi and Kailera Therapeutics. In the amylin space no oral small molecule therapy has been approved and preclinical activity is reported from companies such as Eli Lilly Eccogene Nxera Iktos Cube Biotech Alveus Therapeutics and Ambrosia Biosciences. The company differentiates itself through its proprietary structure based drug discovery platform that integrates three dimensional protein structure visualization with advanced physics based computational methods. This approach enables the design of biased agonists that preferentially activate G protein pathways while avoiding beta arrestin signaling which may improve efficacy and reduce dosing requirements. Manufacturing scalability is another advantage with the stated capacity to produce six thousand tons of aleneglipron per year enough to treat over one hundred twenty million patients annually. The company also maintains a growing patent portfolio with over four hundred eighty patents and patent applications worldwide as of December 2025 providing protection for its product candidates and associated technologies. These factors collectively aim to give Structure Therapeutics Inc a competitive edge in bringing oral small molecule therapies to patients with chronic metabolic cardiovascular and pulmonary diseases.

Structure Therapeutics Inc serves patients who suffer from obesity overweight type two diabetes mellitus and related cardiometabolic conditions such as heart failure sleep apnea chronic kidney disease osteoarthritis metabolic dysfunction associated steatotic liver disease and potentially neurodegenerative disorders. The company’s therapeutic approach aims to provide accessible oral alternatives to injectable peptide therapies thereby addressing issues of patient convenience storage and cost. In addition to patients the company works with collaboration partners that provide essential capabilities and financial support. Key partners include Schrödinger which supplies computational chemistry and modeling expertise and Genentech and Roche which provide licensing rights and upfront financial consideration. These partners are important customers that help fund research development and may participate in future commercialization efforts. The company also anticipates that healthcare providers payors and health systems will become customers once its product candidates receive regulatory approval and reach the market.